ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
121.341,13
0,74%
S&P 500
5.464,62
-0,16%
US Dollar vs BRL
5,44289
0,21%
Bitcoin
64.250,11
0,25%
Brent Oil
84,39
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Cabaletta Bio Inc (CABA)

  7. Cabaletta Bio Inc (CABA) Notícias

CABA

Cabaletta Bio (CABA)

Cabaletta Bio Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CABA
DataHoraFonteTítuloCódigoCompanhia
14/06/202407:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CABACabaletta Bio Inc
14/06/202403:00GlobeNewswire Inc.Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201NASDAQ:CABACabaletta Bio Inc
04/06/202420:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CABACabaletta Bio Inc
29/05/202409:00GlobeNewswire Inc.Cabaletta Bio to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:CABACabaletta Bio Inc
15/05/202408:53Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CABACabaletta Bio Inc
15/05/202408:00GlobeNewswire Inc.Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CABACabaletta Bio Inc
13/05/202409:00GlobeNewswire Inc.Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQNASDAQ:CABACabaletta Bio Inc
21/03/202408:00GlobeNewswire Inc.Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CABACabaletta Bio Inc
20/03/202408:00GlobeNewswire Inc.Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic SclerosisNASDAQ:CABACabaletta Bio Inc
27/02/202410:00GlobeNewswire Inc.Cabaletta Bio to Participate in Upcoming Investor Conferences in MarchNASDAQ:CABACabaletta Bio Inc
14/02/202411:20Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CABACabaletta Bio Inc
01/02/202418:30GlobeNewswire Inc.Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of MyositisNASDAQ:CABACabaletta Bio Inc
31/01/202410:00GlobeNewswire Inc.Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:CABACabaletta Bio Inc
08/01/202409:00GlobeNewswire Inc.Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic SclerosisNASDAQ:CABACabaletta Bio Inc
02/01/202410:00GlobeNewswire Inc.Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:CABACabaletta Bio Inc
29/11/202308:18IH Market NewsAmazon Unveils Innovative Services, Okta Discloses Data Breach, Textron Plans 2% Global Workforce Reduction, and MoreNASDAQ:CABACabaletta Bio Inc
28/11/202318:30GlobeNewswire Inc.Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:CABACabaletta Bio Inc
28/11/202316:59Dow Jones NewsCabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T DrugsNASDAQ:CABACabaletta Bio Inc
20/11/202318:16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CABACabaletta Bio Inc
09/11/202309:00GlobeNewswire Inc.Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CABACabaletta Bio Inc
06/11/202310:15Business WireCellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle PlatformNASDAQ:CABACabaletta Bio Inc
06/11/202309:55Dow Jones NewsCabaletta Bio Gets FDA OK to Study CABA-201 in Generalized Myasthenia GravisNASDAQ:CABACabaletta Bio Inc
06/11/202309:00GlobeNewswire Inc.Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia GravisNASDAQ:CABACabaletta Bio Inc
30/10/202309:00GlobeNewswire Inc.Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in NovemberNASDAQ:CABACabaletta Bio Inc
02/10/202308:00GlobeNewswire Inc.Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201NASDAQ:CABACabaletta Bio Inc
19/09/202309:00GlobeNewswire Inc.Cabaletta Bio to Participate in Upcoming Investor Conferences in SeptemberNASDAQ:CABACabaletta Bio Inc
30/08/202309:00GlobeNewswire Inc.Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in SeptemberNASDAQ:CABACabaletta Bio Inc
22/08/202309:00GlobeNewswire Inc.Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201NASDAQ:CABACabaletta Bio Inc
10/08/202308:57Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CABACabaletta Bio Inc
10/08/202308:00GlobeNewswire Inc.Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CABACabaletta Bio Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:CABA

Seu Histórico Recente

USOTC
RDMMF
Red Metal (PK)
HITB
STXUSD
NASDAQ
RIBT
RiceBran Technologies
TG
A2R882
Asian Development Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados